Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07426913 · ClinicalTrials.gov registry record · NA

Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab

A NA study, sponsored by Virginia Commonwealth University.

Recruiting
Registry status
NA
Development phase
30
Enrollment target

NCT07426913 is a NA study that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07426913, a NA study, is actively recruiting participants, sponsored by Virginia Commonwealth University.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experience (SurviVRSE), designed to help Breast Cancer survivors (n=30) learn about heart health. The aims are to test the usability, feasibility, and acceptability o the intervention. Additionally, follow-up assessments will examine changes in women's cancer therapy related cardiac dysfunction knowledge and heart healthy behaviors (e.g., physical activity).

Interventions

  • BEHAVIORAL Cardiovascular Health Education and Gaming through Virtual Reality

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2026-05-20
Est. Completion 2027-02-28
Phase NA

Sponsor

Virginia Commonwealth University

558 total trials

What the Registry Record Tells You About NCT07426913

The ClinicalTrials.gov registry entry for NCT07426913 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Cardiovascular Health Education and Gaming through Virtual Reality is the first listed.

NCT07426913 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07426913 about?

NCT07426913 is a clinical study titled "Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab". The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experience (SurviVRSE), designed to help Breast Cancer survivors (n=30) learn about heart health. The aims are to test the usability, feasibility, and acceptability o the intervention. Addi...

What is the current status of trial NCT07426913?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2026-05-20. Estimated completion is 2027-02-28.

What interventions are being tested in trial NCT07426913?

The interventions under investigation include: Cardiovascular Health Education and Gaming through Virtual Reality (BEHAVIORAL).

Who is sponsoring clinical trial NCT07426913?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.